secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001104659-24-070470
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Iovance shareholders approve all proposals including equity plan increases at 2024 annual meeting
--------------------------------------------------------------------------------

- All seven director nominees elected; General McPeak did not stand for re-election, no disagreement.
- Advisory vote on executive compensation passed with 173.75M for vs 10.03M against.
- Ratification of Ernst & Young as auditor approved overwhelmingly (223.63M for).
- Amendment to 2018 equity plan to increase authorized shares from 29.7M to 36.7M approved (177.46M for).
- Amendment to 2020 ESPP to increase shares from 1.4M to 1.9M approved (182.04M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924070470/0001104659-24-070470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924070470/tm2416997d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-070470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer